Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer.
Authors
Krebs, Matthew GRenehan, Andrew G
Backen, Alison C
Gollins, S
Chau, I
Hasan, Jurjees
Valle, Juan W
Morris, Karen
Beech, Janette
Ashcroft, Linda
Saunders, Mark P
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology, Cancer Research UK Manchester Institute, Manchester, UKIssue Date
2014-12-31
Metadata
Show full item recordAbstract
Multidrug regimens are active against advanced colorectal cancer (ACRC). However, the increased toxicity requires the use of biomarkers to select the patients who will derive the most benefit. We assessed circulating tumor cells (CTCs) as a prognostic biomarker in patients treated with a 4-drug regimen.Citation
Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer: Clin Colorectal CancerJournal
Clinical Colorectal CancerDOI
10.1016/j.clcc.2014.12.006PubMed ID
25680623Type
ArticleLanguage
enISSN
1938-0674ae974a485f413a2113503eed53cd6c53
10.1016/j.clcc.2014.12.006
Scopus Count
Collections
Related articles
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
- Authors: Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J
- Issue date: 2014 May
- A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
- Authors: Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde L, Abal M, López-López R
- Issue date: 2014 Dec 1
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
- Authors: Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, Stanton L, Radford M, Corkhill A, Griffiths GO, Falk S, Valle JW, O'Reilly D, Siriwardena AK, Hornbuckle J, Rees M, Iveson TJ, Hickish T, Garden OJ, Cunningham D, Maughan TS, Primrose JN, New EPOC investigators
- Issue date: 2020 Mar
- Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
- Authors: Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F
- Issue date: 2018 Apr
- Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
- Authors: Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY
- Issue date: 2012 Mar